Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced continued augmentation of its Special Advisory Committee with the addition of key individuals experienced in highly regulated industries primed for rapid growth. To this accord, the Company announced the appointment of Jay Kheita, ACPR, to its Special Advisory Committee, where he will help lead the integration of Champignon’s novel and natural treatment protocols into its existing consumer packaged goods (“CPGs”) portfolio. Khetia holds pharmacy licenses in Canada, Australia and England and an honors degree in pharmacy specializing in pharmacognosy, the study of medicinal plants, from the University of Brighton. He is also a founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, and is currently a clinical advisor at the Leslie Dan faculty of pharmacy at the University of Toronto. “We are pleased to welcome Jay to Champignon’s Special Advisory Committee, where he will function as a cornerstone advisor throughout our pursuit to develop and deploy precision medicine focused formulations and delivery systems,” Champignon CEO Gareth Birdsall stated in the news release.
To view the full press release, visit http://cnw.fm/PBj4G
About Champignon Brands Inc.
Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor